Brain Cancer Clinical Trials in Philadelphia

Showing 41-60 of 190 trials

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

NCT03251027

This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.

GlioblastomaWHO Grade II GliomaWHO Grade III Glioma

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University100 participantsStarted Jul 2017

Philadelphia, Pennsylvania, United States

TERMINATEDPhase 2< 1 mile

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

NCT05267106

This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal.

GlioblastomaAdult-type Diffuse Gliomas

Incyte Corporation83 participantsStarted May 2022

Beverly Hills, California, United States • Duarte, California, United States • Fullerton, California, United States +76 more locations

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Brain Cancer Trials in Other Cities

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

AB154 Combined With AB122 for Recurrent Glioblastoma

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

9-ING-41 in Pediatric Patients With Refractory Malignancies.

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

Other Conditions in Philadelphia